55.00$
Certificate of Analysis · Batch
BPC-157 is a synthetic pentadecapeptide (15 amino acids, sequence GEPPPGKPADDAGLV) derived from a partial sequence of human body protective compound found in gastric juice. It is stable in gastric acid, which is unusual among peptides, and has been the subject of over two decades of preclinical investigation into cytoprotective and regenerative signaling pathways.
Research models have implicated BPC-157 in modulation of the VEGFR2-Akt-eNOS signaling axis, promotion of angiogenesis, and upregulation of growth factor receptor expression (VEGFR2, FGFR). Rodent studies have examined its effects on gastric ulcer healing, inflammatory bowel disease models, tendon-to-bone and Achilles tendon transection repair, corticosteroid-impaired wound healing, and brain-gut axis signaling. A 2024 pleiotropic-activity review catalogs findings across multiple organ systems including neuroprotection and electrolyte-imbalance counteraction models.
Its stability in human gastric juice and oral bioactivity in animal models is a distinguishing pharmacokinetic feature rarely seen in peptide research and is frequently cited as a reason for its broad experimental interest.
TB-500 is a synthetic peptide corresponding to a bioactive fragment of Thymosin Beta-4, a naturally occurring actin-binding protein. Research interest centers on its actin-regulatory and cell-migration properties, distinct from BPC-157's cytoprotective mechanism.
Preclinical research examines Thymosin Beta-4-derived fragments in the context of cell motility, angiogenesis, and tendon repair models, often studied alongside BPC-157 in tissue-regeneration research protocols. It is important to note in product copy that the commercially available 7-amino-acid fragment differs structurally from the full 43-amino-acid Thymosin Beta-4 molecule studied in earlier human clinical trials for dermal and cardiac repair.
Distinguishing the research fragment from the parent 43-mer molecule is a technical detail that signals scientific rigor to informed researchers.
GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys) first isolated from human plasma. Endogenous levels average approximately 200 ng/mL at age 20, declining to roughly 80 ng/mL by age 60, a decline pattern that originally drove research interest in its regenerative signaling role.
Mechanistic studies describe GHK-Cu as a modulator of multiple cellular pathways including collagen and glycosaminoglycan synthesis, angiogenesis stimulation, antioxidant enzyme upregulation, and anti-inflammatory cytokine modulation. In vivo and in vitro studies have evaluated GHK-Cu-functionalized nanoparticle and hydrogel formulations for accelerated wound closure and antibacterial activity, with one 2024 study reporting over 95% wound closure in an animal re-epithelialization model after 11 days. A registered 2026 clinical trial protocol is evaluating a topical GHK-Cu gel against a vehicle control in acute skin wound models.
The combination of a 50-year research history with an active 2026 clinical trial gives this listing both legacy credibility and current relevance.
KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (alpha-MSH), studied for anti-inflammatory signaling independent of the melanocortin receptor pathway responsible for pigmentation effects.
Preclinical research has examined KPV in models of gut inflammation and cytokine modulation, often in conjunction with other tissue-repair peptides as part of combination research protocols. As a lower-profile research compound relative to BPC-157/TB-500, product copy should focus on its role as a research adjunct within multi-peptide stacks rather than standalone claims.
Framing KPV as a mechanistically distinct anti-inflammatory fragment (versus the pigmentation-associated portion of alpha-MSH) is a useful clarifying point for researchers unfamiliar with the parent hormone.
A combination research formulation pairing two of the most extensively studied tissue-repair peptides, each acting through distinct but potentially complementary mechanisms (VEGFR2-Akt-eNOS signaling for BPC-157; actin regulation for TB-500).
No independent blend-specific efficacy studies exist in the literature; product pages should present each constituent's individual research profile side by side rather than implying a combined or synergistic effect has been directly studied.
This transparency about the evidence gap for blends (vs. single-compound research) builds researcher trust and RUO compliance simultaneously.
A three-peptide research blend combining gastric-derived cytoprotective signaling (BPC-157), actin-regulatory cell motility research (TB-500), and copper-dependent collagen/angiogenesis modulation (GHK-Cu).
As with the two-peptide blend, no combined-formulation studies exist; each constituent's research base should be presented individually on the product page.
Consider a visual breakdown table on the page showing each peptide's individual research area side by side.
A four-peptide research blend adding KPV's anti-inflammatory fragment research to the tissue-repair and collagen-modulation compounds above.
No combined-formulation efficacy data exists; list each constituent's individual literature base per the compliance note above.
This is Prixa's most complex blend SKU — a clear per-peptide breakdown table will likely be the highest-engagement layout for this page.
Retatrutide (also referenced as LY3437943) is a triple receptor agonist engaging glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. Structural biology research has mapped its binding conformation across all three receptors, a novel pharmacological mechanism relative to single- or dual-receptor agonists.
A Phase 2 randomized controlled trial published in NEJM reported dose-dependent effects on body weight and metabolic markers. A follow-up Phase 2a trial in Nature Medicine reported up to an 82% reduction in liver fat in a steatotic liver disease model. A Lancet Diabetes & Endocrinology substudy examined body composition changes, reporting fat mass reduction with lean mass preservation comparable to other agents studied. Mouse model research has further examined its effects in MC4R-deficient obesity models relevant to genetic obesity research.
The 'triple agonist' mechanism is the most technically distinctive feature in this category — researchers interested in receptor pharmacology will find the structural biology angle compelling.
Tirzepatide is a dual GLP-1/GIP receptor agonist, the first dual-incretin agonist studied extensively for glycemic and weight-related research endpoints prior to the emergence of triple-agonist candidates like retatrutide.
Comparative research in genetically obese (MC4R knockout) mouse models has evaluated tirzepatide alongside semaglutide and retatrutide, reporting significant reductions in fat and lean mass alongside favorable changes in insulin and lipid markers across all three agents.
Presenting tirzepatide within a head-to-head comparative research context (vs. semaglutide and retatrutide) helps researchers quickly triangulate mechanism differences.
Semaglutide is a GLP-1 receptor agonist and one of the earliest incretin-based compounds studied in metabolic and obesity research, now used as the pharmacological comparator baseline for newer dual and triple agonists.
Comparative animal studies (MC4R-deficient mouse models) evaluating semaglutide alongside tirzepatide and retatrutide report measurable anti-obesity effects across all three, providing a useful reference point for researchers designing comparative protocols.
As the 'legacy' GLP-1 compound, semaglutide offers researchers the deepest and longest-running comparative dataset in this category.
5-Amino-1MQ is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue that depletes cellular NAD+ pools by methylating nicotinamide.
A key 2013 Nature Chemical Biology study (Ulanovskaya et al.) established that NNMT inhibition in diet-induced obese mice prevented weight gain, reduced fat mass, and increased energy expenditure without altering food intake. A more recent 2024 study in Diabetes, Obesity and Metabolism confirmed dose-dependent limits on body weight and fat mass gain, improved glucose tolerance and insulin sensitivity, and attenuated hepatic steatosis in diet-induced obese mice, alongside full pharmacokinetic characterization.
The 'NAD+ preservation via enzyme inhibition' mechanism is mechanistically distinct from GLP-1 agonism, giving researchers a genuinely different metabolic pathway to study within the same product category.
AOD-9604 is a modified fragment (176-191) of the C-terminus of human growth hormone, engineered to retain lipolytic signaling activity while eliminating the growth-promoting and diabetogenic effects of full-length GH.
Foundational studies in obese mouse models demonstrated that both full-length hGH and AOD-9604 reduced body weight and increased lipolytic sensitivity via interaction with beta-3 adrenergic receptor pathways, with knockout studies confirming beta-3-AR involvement in chronic (but not acute) lipolytic signaling. Human trials have primarily reported safety and tolerability data, with weight-loss efficacy signals described as inconsistent across studies and protocols.
Transparently noting the mixed human efficacy data (versus stronger animal data) reflects the kind of evidence-based nuance that builds credibility with a scientific research audience.
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a peptide encoded within mitochondrial DNA rather than the nuclear genome, identified as a mitochondrial-derived signaling peptide that translocates to the nucleus under metabolic stress.
The foundational 2015 Cell Metabolism study (Lee et al.) identified MOTS-c as a regulator of insulin sensitivity and metabolic homeostasis via AMPK activation, demonstrating prevention of age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mouse models. Subsequent reviews describe its expression in response to exercise and stress, and its regulation of gene expression via the Folate-AICAR-AMPK pathway, with implications explored for skeletal muscle glucose metabolism, aging, and exercise physiology research.
MOTS-c's unique origin as a mitochondrially-encoded (not nuclear-encoded) peptide is a genuinely novel biological concept that tends to capture researcher curiosity immediately.
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to cellular energy metabolism, redox reactions, and substrate signaling for enzymes involved in DNA repair and mitochondrial homeostasis.
Review literature describes an age-associated decline in tissue NAD+ levels observed in a limited number of human studies, with preclinical rodent research showing that NAD+ precursor repletion can extend healthspan markers and mitigate models of premature aging and neurodegeneration. A 2025 review notes that while preclinical data is promising, human clinical trials of NAD+ precursor supplementation have shown limited efficacy to date, highlighting an active and evolving area of translational research.
Presenting NAD+ honestly as an area where preclinical promise has outpaced human trial results signals scientific rigor rather than overselling the compound.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered for extended stability, studied for its stimulatory effects on endogenous growth hormone secretion via the pituitary GHRH receptor.
As a GHRH-receptor-selective compound, tesamorelin is studied for its downstream IGF-1 signaling kinetics and is often used in research protocols as a reference agent for characterizing pulsatile GH release patterns, in contrast to ghrelin-receptor-acting secretagogues.
Its distinct mechanism (natural GHRH receptor agonism vs. synthetic secretagogue action) makes it a useful comparator peptide for researchers studying receptor-selective GH axis modulation.
This blend pairs CJC-1295 (No DAC), a short-acting GHRH analog, with Ipamorelin, a selective growth hormone-releasing peptide (GHRP) acting on the ghrelin receptor. The combination is studied for its potential to engage two distinct receptor pathways governing GH pulsatility.
Research questions of interest for this combination center on whether dual-pathway stimulation (GHRH receptor plus ghrelin receptor) produces additive or synergistic effects on GH pulse amplitude relative to either compound administered alone, an active area of comparative endocrine research.
The 'two distinct receptor pathways acting in concert' framing (GHRH receptor plus ghrelin receptor) is the strongest scientific hook for this blend and differentiates it from single-mechanism secretagogues.
Ipamorelin is a pentapeptide classified as a selective growth hormone secretagogue, acting on the ghrelin receptor (GHS-R) with reported selectivity that limits effects on cortisol and prolactin relative to earlier-generation GHRPs.
Preclinical research has focused on characterizing its receptor selectivity profile and GH pulsatility patterns relative to other growth hormone-releasing peptides, positioning it as a research tool for studying selective ghrelin receptor agonism independent of broader endocrine effects.
Its receptor selectivity profile (versus older, less selective GHRPs) is a key differentiator worth highlighting for researchers comparing secretagogue classes.
Semax is a synthetic heptapeptide analog derived from a fragment of adrenocorticotropic hormone (ACTH 4-10), developed in Russia and studied for central nervous system effects linked to brain-derived neurotrophic factor (BDNF) pathway modulation.
Research literature describes Semax study designs spanning behavioral rodent models and, in some cases, human functional connectivity studies, generally evaluating cognitive and neuroprotective endpoints. It is frequently studied comparatively alongside Selank given their shared Russian peptide-research origin and overlapping CNS research applications.
Its proposed BDNF-pathway mechanism links Semax research to the broader and highly active neurotrophic factor research literature, a useful cross-reference point for researchers.
Selank is a synthetic peptide analog of the endogenous immunomodulatory peptide tuftsin, developed alongside Semax in Russian CNS peptide research and studied primarily for anxiolytic-related effects.
A controlled human study using resting-state functional MRI examined whole-brain functional connectivity changes in 52 healthy volunteers following Selank and Semax administration, focusing on regions of interest including the amygdala, a region central to anxiety-related neurocircuitry research. A related study characterized route-of-administration-dependent predominance of nootropic versus anxiolytic effects across Selank, Semax, and a comparator peptide in mouse models.
The existence of a real human fMRI dataset (rather than only rodent behavioral data) is a distinguishing credibility point that sets this compound apart from many other research peptides.
Epithalon (also spelled Epitalon or Epithalone) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), modeled on the naturally occurring pineal gland extract epithalamin. It has been studied since the early 2000s for its proposed role in telomerase activation.
A foundational 2003 study demonstrated that Epithalon induced expression of the catalytic telomerase subunit and telomere elongation in telomerase-negative human fetal fibroblast cultures, suggesting reactivation of a normally silenced gene in somatic cells. More recent 2025 in vitro research has extended this line of investigation, examining telomerase activation kinetics across multiple cell culture systems using TRAP assay quantification, and separate 2025 research has examined Epithalon's effects on telomerase activity in bovine oocyte models.
The direct line from a 2003 foundational fibroblast study to active 2025 telomerase-kinetics research gives Epithalon a genuinely multi-decade research narrative that researchers interested in cellular aging will find compelling.
All products sold by Prixa Peptides are intended strictly for laboratory research, analytical testing, and educational purposes only. Products are not intended for human consumption, medical use, veterinary use, diagnosis, treatment, or prevention of any disease. It is the responsibility of the purchaser to ensure compliance with all applicable laws, regulations, and guidelines regarding the purchase, handling, and use of these materials.